Navidea Biopharmaceuticals, Inc. Common Stock (NY:NAVB)

N/A UNCHANGED

Last Price Updated: 8:00 PM EDT, Oct 5, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Navidea Biopharmaceuticals, Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >

The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings ↗

March 20, 2022

Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment...

Via Benzinga

Navidea Biopharmaceuticals to Host Fourth Quarter 2021 Earnings Conference Call and Business Update

March 16, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Shares Jump On Research Pact For Tc99m Tilmanocept As Biomarker In Brain Cancer ↗

February 07, 2022

Navidea Biopharmaceuticals Inc (NYSE: NAVB) has

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 04, 2022

On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap...

Via Benzinga

47 Biggest Movers From Yesterday ↗

February 08, 2022

Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT) shares surged 144.6% to close at $7.95 on Monday. The company, on Friday, priced its IPO at $5 per share. Anghami Inc. (NASDAQ: ANGH...

Via Benzinga

Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for Glioblastoma

February 07, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American

February 03, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

January 04, 2022

Good morning, trader! It's time to kick off another day with a dive into the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

December 22, 2021

We've reached the halfway point of the week and we're starting it with an overview of the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx ↗

December 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral...

Via Benzinga

Navidea Biopharmaceuticals Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis

December 16, 2021

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Shares Gain After Terminating Stock Purchase Agreement ↗

December 16, 2021

Navidea Biopharmaceuticals Inc (NYSE: NAVB) has terminated the Stock Purchase Agreement executed on August 30, 2020. The investors agreed to purchase up to $25.0...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

December 16, 2021

Good morning, trader! We're getting right into the swing of things with a breakdown of the biggest pre-market stock movers for Thursday!

Via InvestorPlace

18 Stocks Moving in Thursday's Pre-Market Session ↗

December 16, 2021

Gainers Calliditas Therapeutics AB (NASDAQ: CALT) rose 36.5% to $25.45 in pre-market trading after the company announced it was granted by the FDA accelerated approval of TARPEYO...

Via Benzinga

Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Program

December 15, 2021

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Terminates Stock Purchase Agreement

December 15, 2021

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis

December 13, 2021

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition

December 09, 2021

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results

November 10, 2021

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Wall Street Crime and Punishment: Martin Shkreli, The Self-Destructive Pharma Bro ↗

November 05, 2021

Does crime pay? Wall Street Crime and Punishment is a weekly series by Benzinga's Phil Hall chronicling the bankers, brokers and financial ne’er-do-wells whose ambition...

Via Benzinga

Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update

November 03, 2021

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance ↗

November 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...

Via Benzinga

Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin

October 26, 2021

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Appoints Thomas Forest Farb-Horch and Agnieszka Winkler to the Board of Directors

October 14, 2021

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Looking Into Navidea Biopharmaceutical's Return On Capital Employed ↗

September 28, 2021

According to Benzinga Pro data, during Q2, Navidea Biopharmaceutical (AMEX:NAVB) posted sales of $261.05 thousand. Earnings were up 19.83%, but Navidea Biopharmaceutical still...

Via Benzinga

Navidea Biopharmaceuticals Appoints Michel Mikhail, Ph.D. as Chief Regulatory Officer

September 27, 2021

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

4 Penny Stocks Insiders Are Buying ↗

September 20, 2021

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider...

Via Benzinga

Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition

September 17, 2021

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results

August 11, 2021

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗

August 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.